Kymera Therapeutics (KYMR) COO sells 17,184 pre-planned shares

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. Chief Operating Officer Jeremy G. Chadwick reported selling 17,184 shares of common stock in open-market transactions. The sales occurred on May 26–27, 2026 at weighted-average prices within ranges from about $77.99 to $82.15 per share. A footnote explains that the shares were required to be sold to cover tax withholding obligations tied to vesting restricted stock units and that these sales were automatic, not at his discretion. The transactions were effected under a Rule 10b5-1 trading plan dated December 10, 2025. Following the transactions, Chadwick directly holds 44,018 Kymera shares.

Insider Trade Summary 10b5-1

Net Seller: 17,184 shares ($1,373,290)

Net Sell 7 txns

Insider Chadwick Jeremy G

Role Chief Operating Officer

Sold 17,184 shs ($1.37M)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,679	$81.503	$300K
Sale	Common Stock	600	$82.0767	$49K
Sale	Common Stock	3,730	$78.3569	$292K
Sale	Common Stock	324	$79.17	$26K
Sale	Common Stock	3,800	$79.3923	$302K
Sale	Common Stock	4,500	$80.0246	$360K
Sale	Common Stock	551	$80.7082	$44K

Holdings After Transaction: Common Stock — 44,618 shares (Direct, null)

Footnotes (1)

Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.99 to $78.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.66 to $79.655, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.66 to $80.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.70 to $80.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.985 to $81.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.99 to $82.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 17,184 shares Sale price range: $77.99–$82.15 per share Shares held after: 44,018 shares +1 more

4 metrics

Shares sold 17,184 shares Total common shares sold on May 26–27, 2026

Sale price range $77.99–$82.15 per share Weighted-average trade price ranges noted in footnotes

Shares held after 44,018 shares Direct Kymera common stock holdings after reported sales

Rule 10b5-1 plan date December 10, 2025 Adoption date of the trading plan governing these sales

Key Terms

restricted stock units, Rule 10b5-1 trading plan, weighted average price, open-market sale

4 terms

restricted stock units financial

"cover tax withholding obligations in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

05/27/2026 - 05:50 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chadwick Jeremy G

(Last)

(First)

(Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/26/2026		S⁽¹⁾		3,730	D	$78.3569⁽²⁾	57,472	D
Common Stock	05/26/2026		S⁽¹⁾		324	D	$79.17	57,148	D
Common Stock	05/26/2026		S⁽³⁾		3,800	D	$79.3923⁽⁴⁾	53,348	D
Common Stock	05/26/2026		S⁽³⁾		4,500	D	$80.0246⁽⁵⁾	48,848	D
Common Stock	05/26/2026		S⁽³⁾		551	D	$80.7082⁽⁶⁾	48,297	D
Common Stock	05/27/2026		S⁽³⁾		3,679	D	$81.503⁽⁷⁾	44,618	D
Common Stock	05/27/2026		S⁽³⁾		600	D	$82.0767⁽⁸⁾	44,018	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.99 to $78.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.66 to $79.655, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.66 to $80.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.70 to $80.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.985 to $81.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.99 to $82.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Bruce Jacobs, as Attorney-in-Fact	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Kymera Therapeutics (KYMR) COO report in this Form 4?

Kymera’s COO Jeremy G. Chadwick reported selling 17,184 shares of common stock. The transactions took place on May 26–27, 2026, in multiple open-market sales at weighted-average prices between roughly $78 and $82 per share, according to the Form 4 details and related footnotes.

Why did the Kymera (KYMR) COO sell 17,184 shares of stock?

The Form 4 states the shares were sold to cover tax withholding obligations from vesting restricted stock units. A footnote clarifies the sales were automatic, required for tax purposes, and not made at the personal discretion of the reporting person, Jeremy G. Chadwick.

Were the Kymera (KYMR) COO’s stock sales made under a trading plan?

Yes. A footnote explains the transactions were effected under a Rule 10b5-1 trading plan dated December 10, 2025. Such plans pre-arrange trading activity, indicating these sales followed a pre-established schedule rather than opportunistic timing in the market.

At what prices did the Kymera (KYMR) COO’s Form 4 sales occur?

The filing reports weighted-average sale prices, with footnotes stating individual trades occurred in ranges from $77.99 to $82.15 per share. Each Form 4 line item shows a specific weighted-average price within those ranges for the reported share blocks sold.

How many Kymera (KYMR) shares does the COO hold after these transactions?

After the reported sales, the Form 4 shows Jeremy G. Chadwick directly owning 44,018 shares of Kymera common stock. This post-transaction figure reflects his remaining direct holdings following the 17,184 shares sold to satisfy tax withholding obligations on RSU vesting.

What type of security was involved in the Kymera (KYMR) COO’s Form 4?

All reported transactions involved Kymera Therapeutics common stock. The sales related to shares issued upon vesting of restricted stock units, with subsequent automatic dispositions of a portion of those shares to satisfy associated tax withholding requirements, as described in the footnotes.